Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?
International Journal of Molecular Sciences · 19.05.2023 · 24 (10) · 9020
DOI: 10.3390/ijms24109020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.05.2023. Verfasst von Monica Lispi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Merck Healthcare KGaA, 64293 Darmstadt, Germany. Hauptthemen laut MEDLINE: Biological Products, Infertility. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck (CrossRef Funder ID: 10.13039/100009945).
Abstract (Originalsprache)
Follicle-stimulating hormone (FSH), together with luteinizing hormone (LH) and human chorionic gonadotropin (hCG), plays a fundamental role in human reproduction. The discovery of FSH and other gonadotropins was a defining moment in our understanding of reproduction and led to the development of many treatments for infertility. In this regard, exogenous FSH has been used to treat infertility in women for decades. Today, several recombinant and highly purified urinary forms of FSH are used in medically assisted reproduction (MAR). However, differences in the macro- and micro-heterogeneity of FSH result in a variety of FSH glycoforms, with glycoform composition determining the bioactivity (or potency), pharmacokinetic/pharmacodynamic (PK/PD) profiles, and clinical efficacy of the different forms of FSH. This review illustrates how the structural heterogeneity of FSH glycoforms affects the biological activity of human FSH products, and why potency does not predict effects in humans in terms of PK, PD, and clinical response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck Healthcare KGaA, 64293 Darmstadt, Germany.
- Unit of Endocrinology, PhD School of Clinical and Experimental Medicine, University of Modena and Reggio Emilia, 42121 Reggio Emilia, Italy.
- Fertility Clinic at Skive Regional Hospital, Faculty of Health, Aarhus University, 8000 Aarhus, Denmark.
- Department of Biological Sciences, Wichita State University, Wichita, KS 67260, USA.
- Laboratory of Endometrium, Endometriosis & Reproductive Medicine, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.
- Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University Medical School, New Haven, CT 06510, USA.
ORCID-Profile: Monica Lispi, George R Bousfield, Alfredo Ulloa-Aguirre
Förderung
- Merck (CrossRef Funder ID: 10.13039/100009945)
Zitieren
APA
Lispi, M., Humaidan, P., Bousfield, G. R., D'Hooghe, T., & Ulloa-Aguirre, A. (2023). Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?. International Journal of Molecular Sciences, 24(10), 9020. https://doi.org/10.3390/ijms24109020
Vancouver
Lispi M, Humaidan P, Bousfield GR, D'Hooghe T, Ulloa-Aguirre A. Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?. International Journal of Molecular Sciences. 2023;24(10):9020. doi:10.3390/ijms24109020
BibTeX
@article{Lispi2023,
author = {Lispi, Monica and Humaidan, Peter and Bousfield, George R and D'Hooghe, Thomas and Ulloa-Aguirre, Alfredo},
title = {Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {9020},
doi = {10.3390/ijms24109020}
}
EUVIMED